HIGH-THROUGHPUT DIAGNOSTIC TEST (Diagnostic)
In May 2022, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), MPP signed two licensing agreements with the United States National Institutes of Health (NIH) for the development of 11 innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.
Among these COVID-19 technologies is a diagnostic:
As part of the NIH Rapid Acceleration of Diagnostics (RADx) program, NIEHS researchers developed a genetic sequencing-based test that can combine thousands of biological patient samples to test them for SARS-CoV-2 infection and forecast each patient’s COVID-19 risk in a single run, helping to overcome time constraints. The method, which detects both the virus and the patient’s active genes directly from their swabs, can permit monitoring of at-risk individuals.
MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
|Aim of the licences
|To facilitate the manufacture and commercialisation of Covid-19 related health products and vaccines around the world
|One licence covers different patents and materials on technologies potentially relevant in the fight against COVID-19. The second licence specifically covers patents on the spike protein.
|Any product or vaccine that is covered by the Patents or Patent Applications or uses the Licensed Material.
|Field of use
|While one licence on the different technologies is granted for SARS-CoV-2 products for the WHO C-TAP program, the second licence, in relation to spike protein, refers to SARS-CoV-2 vaccines for the WHO C-TAP program.
|Continuing until the date the last Patent has lapsed, expired, or been invalidated
|Scope of the grant
|Non-exclusive right to grant royalty-bearing sublicences to develop the licensed patents/material into licensed products or vaccines, and to commercialise the licensed products or vaccines
|MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence